Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy

Targeted Oncology

Volumn 1, Issue 1, 2006, Pages 42-53

  Ghoul, A ^a,d   Serova, M ^a,b   Benhadji, K A ^a   Cvitkovic, E ^c   Faivre, S ^d   Philips, E ^a   Calvo, F ^b   Lokiec, F ^a   Raymond, E ^d  

^a CENTRE RENÉ HUGUENIN   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CAC   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

Apoptosis; Cancer; Carcinogenesis; Caspase 3; Cellular signaling; Protein kinase C

Indexed keywords

EID: 33746239638     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-005-0003-0     Document Type: Review

References (157)

1. Hinoda Y, Sasaki S, Ishida T, Imai K (2004) Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95(8):621-625
2. Chen HX (2004) Expanding the Clinical Development of Bevacizumab. Oncologist 9:27-35
3. Geffen DB, Man S (2002) New drugs for the treatment of cancer. Isr Med Assoc J 4(12):1124-1131
4. Mackay HJ, Twelves CJ (2003) Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 10:389-396
5. Koivunen J, Aaltonen V, Koskela S et al (2004) Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res 64(16):5693-5701
6. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281-292
7. Blagden S, de Bono J (2005) Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6:325-335
8. Cohen P (1996) Dissection of protein kinase cascades that mediate cellular response to cytokines and cellular stress. Adv Pharmacol 36:15-27
9. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947
10. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37-40
11. Prenzel N, Fischer OM, Streit S et al (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31
12. Melisi D, Troiani T, Damiano V et al (2004) Therapeutic integration of signal transduction targeting agents and conventional anticancer treatments. Endocr Relat Cancer 11:51-68
13. Ekker LV, Parker PJ (1994) Protein kinase C - a question of specificity. Trends Biochem Sci 19:73-77
14. Musashi M, Ota S, Shiroshita N (2000) The role of protein kinase C isoforms in cell proliferation and apoptosis. Int J Hematol 72(1):12-19
15. Cryns VL, Byun Y, Rana A et al (1997) Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis. Identification by a novel, small pool expression cloning strategy. J Biol Chem 272(47):29449-29453
16. Wetsel WC, Khan WA, Merchenthaler I et al (1992) Tissue and cellular distribution of the extended family of protein kinase C isoenzymes. J Cell Biol 117:121-133
17. Pongracz J, Clark P, Neoptolemos JP, Lord JM (1995) Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 61(1):35-39
18. Fontayne A, My-Chan Dang P, Gougerot-Pocidalo MA, El Benna J (2002) Phosphorylation of p47phox Sites by PKC α, βII, δ and ξ: Effect on Binding to p22phox and on NADPH Oxidase Activation. Biochemistry 41:7743-7750
19. Takai Y, Kishimoto A, Iwasa Y et al (1979) Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J Biol Chem 254:3692-3695
20. Newton AC (1995) Protein kinase C structure, function, and regulation. J Biol Chem 270:28495-28498
21. Swannie HC, Kaye SB (2002) Protein kinase C inhibitors. Curr Oncol Rep 4:37-46
22. Dekker LV, Parker PJ (1994) Protein kinase C: A question of specificity. Trends Biochem Sci 19:73-77
23. Wakelam MJ (1998) Diacylglycerol: when is it an intracellular messenger? Biochim Biophys Acta 1436:117-126
24. Isatnik MH, Hernandez-Sotomayor SM, Jones G et al (1994) Phospholipase C-gamma 1 binding to intracellular receptors for activated protein kinase C. Proc Natl Acad Sci USA 91:559-563
25. Sukai M, Mochly-Rosen D (1999) Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol Res 39:253-259
26. Ay KJ, Chou E, King GL (2000) Identification of PKC isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 21:181-187
27. Evans JD, Cornford PA, Dodson A et al (2003) Expression patterns of protein kinase C isoenzymes are characteristically modulated in chronic pancreatitis and pancreatic cancer. Am J Clin Pathol 119:392-402
28. Brenner W, Farber G, Herget T et al (2003) Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anticancer Res 23:4001-4006
29. Weichert W, Gekeler V, Denkert C et al (2003) Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 23:633-639
30. Kamimura K, Hojo H, Abe M (2004) Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: Relationship between its expression and prognosis. Pathol Int:224-230
31. Blobe GC, Sachs CW, Khan WA et al (1993) Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. J Biol Chem 268:658-664
32. Jaken S (1996) Protein kinase C isozymes and substrates. Curr Opin Cell Biol 8:168-173
33. Schonwasser DC, Marais RM, Marshall CJ et al (1998) Activation of the mitogen-activated protein kinase/extracellular signal-regu-lated kinase pathway by conventional, novel, and atypical protein kinase C. Mol Cell Biol 18:790-798
34. Leevers SJ, Vanhaesebroeck B, Waterfield MD (1999) Signaling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11:219-225
35. Schenk PW, Snaar-Jagalska BE (1999) Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta 1449:1
36. Kolch W, Heidecker G, Kochs G et al (1993) Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364:249-252
37. Ueda Y, Hirai S, Osada S et al (1996) Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271:23512-23519
38. Hafner S, Adler HS, Mischak H et al (1994) Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14 (10):6696-6703
39. Moriya S, Kazlauskas A, Akimoto K et al (1996) Platelet-derived growth factor activates protein kinase Cε through redundant and independent signaling pathways involving phospholipase Cγ or phosphatidylinositol 3-kinase. Cell Biology 93(1):151-155
40. Toker A (1998) Signaling through protein kinase C. Front Biosci: 3:D1134-D1147
41. Marais R, Light Y, Mason C et al (1998) Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 280:109-112
42. Leevers SJ, Vanhaesebroeck B, Waterfield MD (1999) Signaling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11:219-225
43. Yong VW, Krekoski CA, Forsyth PA et al (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21:75-80
44. Fontanini G, Bigini D, Vignati S et al (1995) Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177:57-63
45. Hii CS, Huang ZH, Bilney A et al (1999) Involvement of protein kinase C, p38 MAP kinase and ERK in arachidonic acid-stimulated superoxide production in human neutrophils. Adv Exp Med Biol 469:365-370
46. Lahn MM, Sundell KL (2004) The role of protein kinase C alpha (PKC-α) in melanoma. Melanoma Res 14:85-89
47. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2140
48. Lee JY, Hannun YA, Obeid LM (1996) Ceramide inactivates cellular protein kinase C alpha. J Biol Chem 271:13169-13174
49. Rybin VO, Guo J, Sabri A et al (2004) Stimulus-specific differences in PKC-δ localization and activation mechanisms in cardiomyocytes. J Biol Chem 279:19350-19361
50. Cross T, Griffiths G, Deacon E et al (2000) PKC-delta is an apoptotic lamin kinase. Oncogene 19:2331-2337
51. Hofmann J (2004) Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets 4:125-146
52. Kilpatrick LE, Lee JY, Haines KM et al (2002) A role for PKC-delta and PI 3-kinase in TNF-alpha-mediated antiapoptotic signaling in the human neutrophil. Am J Physiol Cell Physiol 283:48-57
53. Wert MM, Palfrey HC (2000) Divergence in the anti-apoptotic signaling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C delta. Biochem J 352:175-182
54. Ringshausen I, Schneller F, Bogner C et al (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C delta. Blood 100:3741-3748
55. Hussaini IM, Carpenter JE, Redpath GT et al (2002) Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro Oncol 4:9-21
56. Chen CY, Faller DV (1999) Selective inhibition of protein kinase C isozymes by Fas ligation. J Biol Chem 274:15320-15328
57. Beck JF, Brugger D, Brischwein K et al (2001) Anticancer drugmediated induction of multidrug resistanceassociated genes and protein kinase C isozymes in the Tlymphoblastoid cell line CCRFCEM and in blasts from patients with acute lymphoblastic leukemias. Jpn J Cancer Res 92:896-903
58. Fine RL, Patel J, Chabner BA (1988) Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582-586
59. Kazanietz MG (2000) Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinogen 28:5-11
60. O'Brian CA, Ward NE, Gupta KP, Gravitt KR (1995) The contribution of protein kinase C to multiple drug resistance in cancer. In: Kellen JA (ed), Alternative Mechanisms of Multidrug Resistance in Cancer. Birkhaueser Boston: 173-190
61. Yu G, Ahmad S, Aquino A et al (1991) Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 3:181-189
62. Ahmad S, Glazer RI (1993) Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43:858-862
63. Masanek U, Stammler G, Volm M (2002) Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2:37-41
64. Gill PK, Gescher A, Gant TW (2000) Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem 268:4151-4157
65. Goldbrunner RH, Bernstein JJ, Tonn JC (1998) ECM-mediated glioma cell invasion. Microsc Res Tech 43:250-257
66. Rovensky YA (1998) Cellular and molecular mechanisms of tumor invasion. Biochemistry (Mosc) 63:1029-1043
67. Morse-Gaudio M, Connolly JM, Rose DP (1998) Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol 12:1349-1354
68. Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10:2117-2140
69. Yokoyama Y, Ito T, Hanson V et al (1998) PMA-induced reduction in invasiveness is associated with hyperphosphorylation of MARCKS and talin in invasive bladder cancer cells. Int J Cancer 75:774-779
70. Sliva D (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 4:327
71. Ruoslahti E (1997) Integrins as signaling molecules and targets for tumor therapy. Kidney Int 51:1413-1417
72. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ (1998) Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18:790-798
73. Park MJ, Park IC, Hur JH et al (2000) Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 290:201-204
74. Giantonio BJ, Derry C, Mc Aleer C et al (2004) Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin Cancer Res 10(4):1282-1288
75. Zheng X, Chang RL, Cui XX et al (2004) Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64:1811-1820
76. Borner C, Ueffing M, Jaken S et al (1995) Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. J Biol Chem 270:78-86
77. Garzotto M, White-Jones M, Jiang Y et al (1998) 12-O- Tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 58:2260-2264
78. Zheng X, Chang RL, Cui XX et al (2000) Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1α,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 12:419-427
79. Nakashima S, Iwasaki Y, Mizutani T et al (1996) Differential expression of protein kinase C isozymes and small GTP-binding proteins during HL60 cell differentiation by retinoic acid and cyclic AMP: relation with phospholipase D (PLD) activation. Immunobiology 97 196(5):588-598
80. Tamaoki T, Nomoto H, Takahashi I et al (1986) Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem Biophys Res Commun 135:397-402
81. Baltuch GH, Couldwell WT, Villemure JG, Yong VW (1993) Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33(3):495-501
82. Ma D (2001) Recent advances in the discovery of protein kinase C modulators based on the structures of natural protein kinase C activators. Curr Med Chem 8:191-202
83. Fabbro D, Ruetz S, Bodis S et al (2000) PKC412 a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17-28
84. Toullec D, Pianetti P, Coste H et al (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266:15771-15781
85. Clamp A, Jayson GC (2002) The clinical development of the bryostatins. Anticancer Drugs 13:673-683
86. Pettit GR, Herald CL, Doubek DL et al (1982) Isolation and structure of bryostatin-1. J Am Chem Soc 104:6846-6848
87. Hennings H, Blumberg PM, Pettit GR et al (1987) Bryostatin-1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8:1343-1346
88. Blois JT, Mataraza JM, Mecklenbraük I et al (2004) B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase C-δ. J Biol Chem 279(29):30123-30132
89. Varterasian ML, Mohammad RM, Eilender DS et al (1998) Phase I study of bryostatin-1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. J Clin Oncol 16(1):56-62
90. Varterasian ML, Mohammad RM, Shurafa MS et al (2000) Phase II trial of bryostatin-1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 6(3):825-828
91. Mohanty S, Huang J, Basu A (2005) Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. Clin Cancer Res 11(18):6730-6737
92. Ivashchenko Y, Kramer F, Schafer S et al (2005) Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes. Arterioscler Thromb Vasc Biol 25(1):186-192
93. Brandt S, Heller H, Schuster KD, Grote J (2005) The tamoxifen-induced suppression of telomerase activity in the human hepatoblastoma cell line HepG2: a result of posttranslational regulation. J Cancer Res Clin Oncol 131(2):120-128
94. Lara PN Jr, Gandara DR, Wurz GT et al (1998) High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol 42:504-508
95. Kedei N, Lundberg DJ, Toth A et al (2004) Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res 64:3243-3255
96. Hampson P, Chahal H, Khanim F et al (2005) PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106:1362-1368
97. Tortora G, Ciardiello F (2003) Antisense strategies targeting protein kinase C: preclinical and clinical development. Semin Oncol 30(Suppl 10):23-26
98. Shen L, Dean NM, Glazer RI (1999) Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase C-α antisense oligonucleotide. Mol Pharmacol 55:396-402
99. Monnerat C, Le Chevalier T, Kelly K et al (2004) Phase II Study of pemetrexed-gemcitabine combination in patients with advancedstage non-small cell lung cancer. Clin Cancer Res 10 (16):5439-5446
100. Cao Y, Xia QH, Meng H, Zhong AP (2005) Antitumor and synergistic effect of Chinese medicine "Bushen huayu jiedu recipe" and chemotherapy on transplanted animal hepatocarcinoma. World J Gastroenterol 11(33):5218-5220
101. Tortora G, Ciardiello F (2003) Antisense strategies targeting protein kinase C: preclinical and clinical development. Semin Oncol 4(10):26-31
102. Matsumoto T, Tani E, Yamaura I et al (1995) Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 36(3):565-571
103. Aggarwal S, Lee S, Mathur A et al (1994) 12-Deoxyphorbol-13-O- phenylacetate 20 acetate [an agonist of protein kinase C beta 1 (PKC beta 1)] induces DNA synthesis, interleukin-2 (IL-2) production, IL-2 receptor alpha-chain (CD25) and beta-chain (CD122) expression, and translocation of PKC beta isozyme in human peripheral blood lymphocytes: evidence for a role of PKC beta 1 in human T cell activation. J Clin Immunol 14(4):248-256
104. Franklin CC, Kraft AS (1997) Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 272:16917-16923
105. Lordanov MS, Pribnow D, Magun JL et al (1998) Ultraviolet radiation triggers the ribotoxic stress response in mammalian cells. J Biol Chem 273:15794-15803
106. Zhao X, Murata T, Ohn S et al (2001) Protein Kinase C-α plays a critical role in mannosylerythritol lipid-induced differentiation of melanoma B16 cells. J Biol Chem 276 (43):39903-39910
107. Jun DW, Moon JY, Baeg SH et al (2005) A clinical study of pyogenic liver abscess at two different local hospitals. Korean J Hepatol 11(3):250-260
108. Klecha AJ, Salgueiro J, Wald M et al (2005) In vivo iron and zinc deficiency diminished T- and B-selective mitogen stimulation of murine lymphoid cells through protein kinase C-mediated mechanism. Biol Trace Elem Res 104(2):173-183
109. Palecek SP, Loftus JC, Ginsberg MH et al (1997) Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature (London) 385:537-540
110. Chapline C, Cottom J, Tobin H et al (1998) A major, transformation- sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling. J Biol Chem 273:19482-19489
111. Haller H, Lindschau C, Maasch C et al (1998) Integrin-induced protein kinase C alpha and Cepsilon translocation to focal adhesions mediates vascular smooth muscle cell spreading. Circ Res 82:157-165
112. Sun XG, Rotenberg SA (1999) Overexpression of PKC-α in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility. Cell Growth Differ 10:343-352
113. Dumont JA, Bitonti AJ (1994) Modulation of human melanoma cell metastasis and adhesion may involve integrin phosphorylation mediated through protein kinase C. Biochem Biophys Res Commun 204:264-272
114. Dean N, McKay R, Miraglia L et al (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Research 56:3499-3507
115. Chakrabarty S, Rajagopal S, Moskal TL (1998) Protein kinase C-α controls the adhesion but not the antiproliferative response of human colon carcinoma cells to transforming growth factor beta1: identification of two distinct branches of post-protein kinase C alpha adhesion signal pathway. Lab Invest 78(4):413-421
116. Harrington EO, Loffler J, Nelson PR et al (1997) Enhancement of migration by protein kinase C-α and inhibition of proliferation and cell cycle progression by protein kinase C-δ in capillary endothelial cells. J Biol Chem 272:7390-7397
117. Sullivan RM, Stone M, Marshall JF et al (2000) Photo-induced inactivation of protein kinase C alpha by dequaliniuminhibits motility of murine melanoma cells. Mol Pharmacol 58(4):729-737
118. Ueda Y, Syu-ichi Hirai, Osada SI et al (1996) Protein kinase C-δ activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. The American Society for Biochemistry and Molecular Biology 271(38):23512-23519
119. Ashton AW, Watanabe G, Albanese C et al (1999) Protein kinase C-δ inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem 274:20805-20811
120. Stetak A, Lankenau A, Vantus T et al (2001) The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKC-δ and c-Src. Biochem Biophys Res Commun 285:483-488
121. Griffiths G, Garrone B, Deacon E et al (1996) The polyether bistratene A activates protein kinase C-δ and induces growth arrest in HL60 cells. Biochem Biophys Res Commun 222:802-808
122. Watters D, Garrone B, Coomer J et al (1998) Stimulation of melanogenesis in a human melanoma cell line by bistratene A. Biochem Pharmacol 55:1691-1699
123. McCracken MA, Miraglia LJ, McKay RA, Strobl JS (2003) Protein kinase C-δ is a pro-survival factor in human breast tumor cell lines. Mol Cancer Ther 2:273-281
124. Kumar V, Pandey P, Sabatini D et al (2000) Functional interaction between RAFT1/FRAP/mTOR and protein kinase C-δ in the regulation of cap-dependent initiation of translation. EMBO J 19:1087-1097
125. Schmelzie T, Hall MN (2000) TOR, a controller of cell growth. Cell 103:253-262
126. Keshamouni VG, Mattingly RR, Reddy KB (2002) Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 and PKC-δ. J Biol Chem 277:22558-22565
127. Corbit KC, Foster DA, Rosner MR (1999) Protein kinase C-δ mediates neurogenic but not mitogenic activation of mitogen-activated protein kinase in neuronal cells. Mol Cell Biol 19:4209-4218
128. Ueda Y, Hirai S, Osada S et al (1996) Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271: 23512-23519
129. Zang Q, Lu Z, Curto M et al (1997) Interaction between v-Src and protein kinase C-δ in v-Src-transformed fibroblasts. J Biol Chem 272:13275-13280
130. Song JS, Swann PG, Szallasi Z et al (1998) Tyrosine phosphorylation- dependent and -independent associations of protein kinase C-δ with Src family kinases in the RBL-2H3 mast cell line: regulation of Src family kinase activity by protein kinase C-δ. Oncogene 16:3357-3368
131. Zhong M, Lu Z, Abbas T et al (2001) Novel tumor-promoting property of tamoxifen. Cell Growth Differ 12:187-192
132. Kronfeld I, Kazimirsky G, Lorenzo PS et al (2000) Phosphorylation of PKC-δ on distinct tyrosine residues regulates specific cellular functions. J Biol Chem 275:35491-35498
133. Yuan ZM, Utsugisawa T, Ishiko T et al (1998) Activation of protein kinase C-δ by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene 16:1643-1648
134. Li W, Jiang YX, Zhang J et al (1998) Protein kinase C-δ is an important signaling molecule in insulin-like growth factor I receptormediated cell transformation. Mol Cell Biol 18:5888-5898
135. Datta K, Nambudripad R, Pal S et al (2000) Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem 275:20700-20706
136. Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76:61-119
137. Gschwendt M, Kielbassa K, Kittstein W, Marks F (1994) Tyrosine phosphorylation and stimulation of protein kinase C-δ from porcine spleen by src in vitro. Dependence on the activated state of protein kinase C-δ. FEBS Lett 347:85-89
138. Shanmugam M, Krett NL, Peters CA et al (1998) Association of PKC-δ and active Src in PMA-treated MCF-7 human breast cancer cells. Oncogene 16:1649-1654
139. Sun X, Wu F, Datta R et al (2000) Interaction between protein kinase C-δ and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem 275:7470-7473
140. DeVries TA, Neville MC, Reyland ME (2002) Nuclear import of PKC-δ is required for apoptosis: identification of a novel nuclear import sequence. EMBO J 21:S 6050-S 6060
141. Abbas T, White D, Hui L et al (2004) Inhibition of human p53 basal transcription by down-regulation of protein kinase C-δ. J Biol Chem 279. In press
142. Emoto Y, Manome Y, Meinhardt G et al (1995) Proteolytic activation of protein kinase C-δ by an ICE-like protease in apoptotic cells. EMBO J 14:6148-6156
143. Ghayur T, Hugunin M, Talanian RV et al (1996) Proteolytic activation of protein kinase C-δ by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 184:2399-2404
144. Blass M, Kronfeld I, Kazimirsky G et al (2002) Tyrosine phosphorylation of protein kinase C-δ is essential for its apoptotic effect in response to etoposide. Mol Cell Biol 22: 182-195
145. Ren J, Datta R, Shioya H et al (2002) p73δ is regulated by protein kinase C catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem 277:33758-33765
146. Basu A, Woolard MD, Johnson CL (2001) Involvement of protein kinase C delta in DNA damage-induced apoptosis. Cell Death Differ 8:899-908
147. Bharti A, Kraeft S-K, Gounder M et al (1998) Inactivation of DNA-dependent protein kinase by protein kinase C-δ: implications for apoptosis. Mol Cell Biol 18:6719-6728
148. Yuan ZM, Utsugisawa T, Ishiko T et al (1998) Activation of protein kinase C-δ by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene 16:1643-1648
149. Duan H, Dixit VM (1997) RAIDD is a new "death" adaptor molecule. Nature 385:86-89
150. Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC-delta promotes cellular survival and chemotherapeutic resistance. Cancer Res 63:780-786
151. Li C, Werni F, Leitges M, Hu Y, Xu Q (2003) Mechanical stress-activated PKC regulates smooth muscle cell migration. FASEB J 17(14):2106-2108
152. Tortora G, Ciardiello F (2003) Antisense strategeries targeting protein kinase C: preclinical development. Seminar in Oncology 30(10):26-31
153. Mohanty A, Huang J, Basu A (2005) Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin-1. Clin Cancer Res 11
154. Kronfeld I, Kazimirsky G, Lorenzo PS et al (2000) Phosphorylation of protein kinase C-delta on distinct tyrosine residues regulates specific cellular functions. J Biol Chem 275 (45):35491-35498
155. Bharti A, Kraeft SK, Gounder M et al (1998) Inactivation of DNA-dependent protein kinase by protein kinase C-δ: implications for apoptosis. Mol Cell Biol 18:6719-6728
156. Jackson DN, Foster DA (2004) The enigmatic protein kinase C-δ: complex roles in cell proliferation and survival. The FASEB Journal 18:627-636
157. Godbout JP, Pesavento J, Hartman ME et al (2001) Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase C delta. J Biol Chem 277(4):2554-2561